PTOISBIBB (08-03)
Approved for use through 977312086 (108-06-103)
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
ond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to resp Application Number F

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application (tulliber		
Filing Date		
First Named Inventor	Gerh	ard Auer
Art Unit		_
Examiner Name		
Attornov Docket Numb	or	AP112.06

					U.S.I	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue E	Date	Name of Patentee or Applicant of cited Document		Releva	Columns,Lin ant Passages s Appear		
	1	4226214	A	1980-1	0-07	Palazzetti et a	4.				
	2	4992669	A	1991-0	2-12	Parmiey et al.					
	3	5497615	A	1996-0	3-12	Noe et al.					
If you wis	h to a	d additional U.S. Pater	t citatio	n inform	ation pl	ease click the	Add button.	_	Add		
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ition	Name of Patentee or Applicant of cited Document			,Columns,Lin ant Passages s Appear		
	1										
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	olease click the Ad	d button	Add		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Colum where Releva Passages or Figures Appe	ant Relevant	Тs
	1	3528148	DE		A1	1987-02-19	FA. Hermann Silbernagel				

				Application Number						
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)			Filing Date							
			First Named Inventor Gerh			Gert	ard Auer			
			Art Unit							
			Examiner Name							
			Attorney Docket Number			er	AP112-06			
	2	19944237	DE		A1	2001-03-2	29	Domier GMBH		
	3	1507908	GB		А	1978-04-1		Kloeckner Humboldt Deutz		

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Initials*

No publisher, city and/or country where published.

Add

If you wish to add additional Foreign Patent Document citation information please click the Add button

If you wish to add additional non-patent literature document citation information please click the Add button Add

FXAININES SIGNATURE

Examiner Signature | Date Considered |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a

citation if not in conformance and not considered. Include copy of this form with next communication to applicant

See Not Code of USPTO Pearl Documents at leave USPTO_DGUY on NETS 90.04. Tester of this that issued the document, by the two-lefter code (NIPO) Searched 37.3). "For Uspharese pearls counted in the addication of the year of the insign of the Emperor must preciod the sental number of the patient document." Viold of focusined by the appropriate symbols as indicated on the document under VMPO Standard 37.4 of possion. "Application is to place a credit counter."

Application Number Filing Date Filing Date Filing Date First Number Inventor Gerhard Auer Art Unit Examiner Name Attorney Docket Number | AP112-06

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to	make the	appropriate selection(s):
---------------	----------	-------------	----------	-------------------------	----

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 1.97(eVI.)

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/5(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/9/(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/David A. Guerra/	Date (YYYY-MM-DD)	2006-09-19
Name/Print	David A. Guerra	Registration Number	46443

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S. 2213.1-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313.1-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.